|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng J, Meng J, Zhu L and Peng Y:
Exosomal noncoding RNAs in Glioma: Biological functions and
potential clinical applications. Mol Cancer. 19:662020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xie Y, Su N, Yang J, Tan Q, Huang S, Jin
M, Ni Z, Zhang B, Zhang D, Luo F, et al: FGF/FGFR signaling in
health and disease. Signal Transduct Target Ther. 5:1812020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Foley JF, Kennedy BJ and Ross JD: A factor
from HeLa cells promoting colonial growth of human fibroblast-like
cells in culture. Cancer Res. 23:368–371. 1963.PubMed/NCBI
|
|
6
|
Gospodarowicz D: Localisation of a
fibroblast growth factor and its effect alone and with
hydrocortisone on 3T3 cell growth. Nature. 249:123–127. 1974.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Presta M, Chiodelli P, Giacomini A,
Rusnati M and Ronca R: Fibroblast growth factors (FGFs) in cancer:
FGF traps as a new therapeutic approach. Pharmacol Ther.
179:171–187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giacomini A, Chiodelli P, Matarazzo S,
Rusnati M, Presta M and Ronca R: Blocking the FGF/FGFR system as a
‘two-compartment’ antiangiogenic/antitumor approach in cancer
therapy. Pharmacol Res. 107:172–185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Presta M, Dell'Era P, Mitola S, Moroni E,
Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth
factor receptor system in angiogenesis. Cytokine Growth Factor Rev.
16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jimenez-Pascual A, Mitchell K,
Siebzehnrubl FA and Lathia JD: FGF2: A novel druggable target for
glioblastoma? Expert Opin Ther Targets. 24:311–318. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haley EM and Kim Y: The role of basic
fibroblast growth factor in glioblastoma multiforme and
glioblastoma stem cells and in their in vitro culture. Cancer Lett.
346:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bian XW, Du LL, Shi JQ, Cheng YS and Liu
FX: Correlation of bFGF, FGFR-1 and VEGF expression with
vascularity and malignancy of human astrocytomas. Anal Quant Cytol
Histol. 22:267–274. 2000.PubMed/NCBI
|
|
13
|
Joy A, Moffett J, Neary K, Mordechai E,
Stachowiak EK, Coons S, Rankin-Shapiro J, Florkiewicz RZ and
Stachowiak MK: Nuclear accumulation of FGF-2 is associated with
proliferation of human astrocytes and glioma cells. Oncogene.
14:171–183. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toyoda K, Tanaka K, Nakagawa S, Thuy DH,
Ujifuku K, Kamada K, Hayashi K, Matsuo T, Nagata I and Niwa M:
Initial contact of glioblastoma cells with existing normal brain
endothelial cells strengthen the barrier function via fibroblast
growth factor 2 secretion: A new in vitro blood-brain barrier
model. Cell Mol Neurobiol. 33:489–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pollard SM, Yoshikawa K, Clarke ID, Danovi
D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, et
al: Glioma stem cell lines expanded in adherent culture have
tumor-specific phenotypes and are suitable for chemical and genetic
screens. Cell Stem Cell. 4:568–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyagi N, Kato S, Terasaki M, Shigemori M
and Morimatsu M: Fibroblast growth factor-2 and −9 regulate
proliferation and production of matrix metalloproteinases in human
gliomas. Int J Oncol. 12:1085–1090. 1998.PubMed/NCBI
|
|
17
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X,
Zhong J, Zhao Z, Zhao K, Liu D, et al: Circular RNA-encoded
oncogenic E-cadherin variant promotes glioblastoma tumorigenicity
through activation of EGFR-STAT3 signalling. Nat Cell Biol.
23:278–291. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ornitz DM and Itoh N: The Fibroblast
Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol.
4:215–266. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Flanders KC, Lüdecke G, Renzing J, Hamm C,
Cissel DS and Unsicker K: Effects of TGF-betas and bFGF on
astroglial cell growth and gene expression in vitro. Mol Cell
Neurosci. 4:406–417. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou YJ, Yu AC, Garcia JM, Aotaki-Keen A,
Lee YL, Eng LF, Hjelmeland LJ and Menon VK: Astrogliosis in
culture. IV. Effects of basic fibroblast growth factor. J Neurosci
Res. 40:359–370. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reuss B, Dono R and Unsicker K: Functions
of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial
differentiation and blood-brain barrier permeability: Evidence from
mouse mutants. J Neurosci. 23:6404–6412. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loilome W, Joshi AD, ap Rhys CM,
Piccirillo S, Vescovi AL, Gallia GL and Riggins GJ: Glioblastoma
cell growth is suppressed by disruption of Fibroblast Growth Factor
pathway signaling. J Neurooncol. 94:359–366. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stan AC, Nemati MN, Pietsch T, Walter GF
and Dietz H: In vivo inhibition of angiogenesis and growth of the
human U-87 malignant glial tumor by treatment with an antibody
against basic fibroblast growth factor. J Neurosurg. 82:1044–1052.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gasser E, Sancar G, Downes M and Evans RM:
Metabolic Messengers: Fibroblast growth factor 1. Nat Metab.
4:663–671. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sancar G, Liu S, Gasser E, Alvarez JG,
Moutos C, Kim K, van Zutphen T, Wang Y, Huddy TF, Ross B and Dai Y:
FGF1 and insulin control lipolysis by convergent pathways. Cell
Metab. 34:171–183.e6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Uriel S, Brey EM and Greisler HP:
Sustained low levels of fibroblast growth factor-1 promote
persistent microvascular network formation. Am J Surg. 192:604–609.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Hariry I, Pignatelli M and Lemoine NR:
FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins
in pancreatic adenocarcinoma. Int J Cancer. 94:652–661. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao D, Lu Y, Yang C, Zhou X and Xu Z:
Activation of FGF receptor signaling promotes invasion of
non-small-cell lung cancer. Tumour Biol. 36:3637–3642. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
King ML, Lindberg ME, Stodden GR, Okuda H,
Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA and Hayashi
K: WNT7A/β-catenin signaling induces FGF1 and influences
sensitivity to niclosamide in ovarian cancer. Oncogene.
34:3452–3462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zubor P, Hatok J, Moricova P, Kajo K,
Kapustova I, Mendelova A, Racay P and Danko J: Gene expression
abnormalities in histologically normal breast epithelium from
patients with luminal type of breast cancer. Mol Biol Rep.
42:977–988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ke J, Yao YL, Zheng J, Wang P, Liu YH, Ma
J, Li Z, Liu XB, Li ZQ, Wang ZH and Xue YX: Knockdown of long
non-coding RNA HOTAIR inhibits malignant biological behaviors of
human glioma cells via modulation of miR-326. Oncotarget.
6:21934–2149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Katoh M and Katoh M: Comparative genomics
on FGF8, FGF17, and FGF18 orthologs. Int J Mol Med. 16:493–496.
2005.PubMed/NCBI
|
|
35
|
Iram T, Kern F, Kaur A, Myneni S,
Morningstar AR, Shin H, Garcia MA, Yerra L, Palovics R, Yang AC, et
al: Young CSF restores oligodendrogenesis and memory in aged mice
via Fgf17. Nature. 605:509–515. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heer R, Douglas D, Mathers ME, Robson CN
and Leung HY: Fibroblast growth factor 17 is over-expressed in
human prostate cancer. J Pathol. 204:578–586. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen J, Wang X, Hu J, Du J, Dordoe C, Zhou
Q, Huang W, Guo R, Han F, Guo K, et al: FGF20 Protected Against BBB
disruption after traumatic brain injury by upregulating junction
protein expression and inhibiting the inflammatory response. Front
Pharmacol. 11:5906692021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boshoff EL, Fletcher EJR and Duty S:
Fibroblast growth factor 20 is protective towards dopaminergic
neurons in vivo in a paracrine manner. Neuropharmacology.
137:156–163. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dono R: Fibroblast growth factors as
regulators of central nervous system development and function. Am J
Physiol Regul Integr Comp Physiol. 284:R867–R881. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Niu J, Xie J, Guo K, Zhang X, Xia F, Zhao
X, Song L, Zhuge D, Li X, Zhao Y and Huang Z: Efficient treatment
of Parkinson's disease using ultrasonography-guided rhFGF20
proteoliposomes. Drug Deliv. 25:1560–1569. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cai X, Tao W and Li L: Glioma cell-derived
FGF20 suppresses macrophage function by activating β-catenin. Cell
Signal. 89:1101812022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dabrowski A, Terauchi A, Strong C and
Umemori H: Distinct sets of FGF receptors sculpt excitatory and
inhibitory synaptogenesis. Development. 142:1818–1830. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pasaoglu T and Schikorski T: Presynaptic
size of associational/commissural CA3 synapses is controlled by
fibroblast growth factor 22 in adult mice. Hippocampus. 26:151–160.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aljović A, Jacobi A, Marcantoni M, Kagerer
F, Loy K, Kendirli A, Bräutigam J, Fabbio L, Van Steenbergen V,
Pleśniar K, et al: Synaptogenic gene therapy with FGF22 improves
circuit plasticity and functional recovery following spinal cord
injury. EMBO Mol Med. 15:e161112023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jacobi A, Loy K, Schmalz AM, Hellsten M,
Umemori H, Kerschensteiner M and Bareyre FM: FGF22 signaling
regulates synapse formation during post-injury remodeling of the
spinal cord. EMBO J. 34:1231–1243. 2015. View Article : Google Scholar : PubMed/NCBI
|
